Mohamed Mohamed, MD
Hematology · Greensboro, NCNPI 1346293784
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $638,349 of the $841,353 with a category attached, or 75.9%. It is spread thinly across 30 manufacturers, the largest accounting for just 23.6%. Reporting peaked in 2022 at $176,360 and has fallen 62.7% since, to $65,769 in 2025. Among hematology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 860 payments — averaging $978.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$199K
- E.r. Squibb & Sons, L.L.C.$127K
- Regeneron Healthcare Solutions, Inc.$103K
- Lilly USA, LLC$97K
- G1 Therapeutics, Inc.$85K
- Sanofi$50K
- plus $181K from 24 others
Across 63 payments — averaging $4713.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$171K
- E.r. Squibb & Sons, L.L.C.$63K
- GSK$24K
- AstraZeneca$22K
- AbbVie$18K
What the payments were for
- Consulting fees$108,26813%
- Speaking & faculty fees$638,34976%
- Travel & lodging$78,7029%
- Food & beverage$15,2602%
- Education$7750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 165 | $198,663 |
| E.r. Squibb & Sons, L.L.C. | 122 | $127,050 |
| Regeneron Healthcare Solutions, Inc. | 84 | $102,599 |
| Lilly USA, LLC | 177 | $96,546 |
| G1 Therapeutics, Inc. | 63 | $85,095 |
| Sanofi | 38 | $49,945 |
| Mirati Therapeutics, Inc. | 32 | $38,838 |
| Johnson & Johnson | 38 | $26,492 |
| Merck | 30 | $22,689 |
| Amgen | 20 | $19,157 |
| AbbVie | 9 | $14,221 |
| Pharmacosmos Therapeutics Inc. | 10 | $13,117 |
| Novocure Inc. | 15 | $11,231 |
| Boehringer Ingelheim | 10 | $9,022 |
| Pfizer | 7 | $7,084 |
| Daiichi Sankyo Inc. | 5 | $5,165 |
| Eli Lilly | 8 | $4,907 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $2,654 |
| Genentech USA, Inc. | 7 | $2,353 |
| Bristol Myers Squibb | 4 | $1,908 |
| EMD Serono, Inc. | 1 | $1,725 |
| Galvanize Therapeutics, Inc | 2 | $242 |
| Intuitive Surgical | 2 | $173 |
| Auris Health, Inc. | 1 | $120 |
| Caris MPI, Inc. | 1 | $107 |
| Astellas Pharma Global Development | 1 | $98 |
| Abbott | 1 | $95 |
| Incyte Corporation | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Legend Biotech USA Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$141,983
- TAGRISSO$104,644
- OPDIVO$103,803
- COSELA$97,505
- IMFINZI$72,804
- KRAZATI$38,617
- ALIMTA$25,113
- RYBREVANT$23,242
- KEYTRUDA$16,791
- CYRAMZA$16,603
- LUMAKRAS$16,077
- EMRELIS$11,821
- OPTUNE LUA (NOVOTTF-200T)$10,905
- CARVYKTI$10,048
- Enhertu$9,687
- GILOTRIF$8,886
- RETEVMO$8,068
- LORBRENA$5,990
- TECENTRIQ$2,174
- ULTOMIRIS$265
How this compares
$841,353 in reported general payments places this provider in the 95th percentile of 65 hematology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 75 | $1,252,235 |
| Lenalidomide | 53 | $766,770 |
| AlecensaAlectinib Hcl | 22 | $369,650 |
| CabometyxCabozantinib S-Malate | 14 | $340,713 |
| PomalystPomalidomide | 13 | $307,150 |
| KrazatiAdagrasib | 14 | $287,338 |
| GilotrifAfatinib Dimaleate | 15 | $167,338 |
| XalkoriCrizotinib | 12 | $133,813 |
| EliquisApixaban | 53 | $39,523 |
| Erlotinib Hcl | 53 | $16,534 |
| Imatinib Mesylate | 13 | $3,129 |
| Prochlorperazine Maleate | 147 | $1,474 |
| Hydroxyurea | 51 | $1,229 |
| Dexamethasone | 72 | $1,219 |
| Fentanyl | 19 | $679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $198,663 | $1,252,23575 claims |
| Genentech USA, Inc.Alecensa | $2,353 | $369,65022 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $127,050 | $307,15013 claims |
| Mirati Therapeutics, Inc.Krazati | $38,838 | $287,33814 claims |
| PfizerXalkori, Eliquis | $7,084 | $173,33665 claims |
| Boehringer IngelheimGilotrif | $9,022 | $167,33815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 65 hematology providers in North Carolina.
Other hematology in Greensboro
- James GranfortunaGreensboro$377
- Ryan JacobsCharlotte$1.5M
- Alan Zausner SkarbnikCharlotte$1.1M
- Raymond ThertulienCharlotte$561K
- Ruben MesaCharlotte$384K
- Michael GrunwaldCharlotte$344K
- Franklin ChenWinston Salem$307K
- Nilay ShahCharlotte$228K
- James DuganWinston Salem$200K
- Peter VoorheesCharlotte$157K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.